Halpern Alfredo, Pepe Renata B, Monegaglia Ana Paola, Beyruti Mônica, de Melo Maria Edna, Mancini Marcio C
Group of Obesity & Metabolic Syndrome, Endocrinology Service, Hospital das Clínicas, Faculty of Medicine, University of Sao Paulo, 05410-000 São Paulo, Brazil.
J Obes. 2010;2010. doi: 10.1155/2010/602537. Epub 2010 Feb 7.
Objective. To assess the efficacy and tolerability of the association sibutramine (10-20 mg/day) and orlistat (120 mg 2-3 times a day) in the treatment of obesity in a six-month open trial. Methods. 446 overweight and obese patients who sought treatment for obesity in a private clinic were assessed every 2 weeks during a period of 3 and 6 months. Results. After 3 months, the mean weight loss was 10.5 kg (-9.8% of the initial weight, n = 263), and after 6 months, the mean weight loss was 13.9 kg (-12.8% of the initial weight, n = 97). The tolerability of such association was quite acceptable and coherent with the action mechanism of each component. Conclusions. The association of orlistat and sibutramine is quite efficient and it seems to promote a higher rate of weight loss than that reported in clinical studies performed with each drug separately.
目的。在一项为期六个月的开放试验中，评估西布曲明（10 - 20毫克/天）与奥利司他（120毫克，每日2 - 3次）联合使用治疗肥胖症的疗效和耐受性。方法。在一家私人诊所寻求肥胖症治疗的446名超重和肥胖患者，在3个月和6个月的期间内每2周进行一次评估。结果。3个月后，平均体重减轻10.5千克（占初始体重的 - 9.8%，n = 263），6个月后，平均体重减轻13.9千克（占初始体重的 - 12.8%，n = 97）。这种联合用药的耐受性相当良好，且与每种成分的作用机制相符。结论。奥利司他和西布曲明联合使用相当有效，且似乎比分别使用每种药物进行的临床研究报告的减重率更高。
Zotero 插件
